- Home
- NUW vs AVIR Comparison
NUW vs AVIR Comparison
Compare NUW & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- AVIR
- Stock Information
- Founded
- NUW 2008
- AVIR 2012
- Country
- NUW United States
- AVIR United States
- Employees
- NUW N/A
- AVIR N/A
- Industry
- NUW Investment Managers
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- NUW Finance
- AVIR Health Care
- Exchange
- NUW Nasdaq
- AVIR Nasdaq
- Market Cap
- NUW 246.8M
- AVIR 277.8M
- IPO Year
- NUW N/A
- AVIR 2020
- Fundamental
- Price
- NUW $13.68
- AVIR $3.50
- Analyst Decision
- NUW
- AVIR Hold
- Analyst Count
- NUW 0
- AVIR 1
- Target Price
- NUW N/A
- AVIR $6.00
- AVG Volume (30 Days)
- NUW 45.3K
- AVIR 361.0K
- Earning Date
- NUW 01-01-0001
- AVIR 08-07-2025
- Dividend Yield
- NUW 3.66%
- AVIR N/A
- EPS Growth
- NUW N/A
- AVIR N/A
- EPS
- NUW N/A
- AVIR N/A
- Revenue
- NUW N/A
- AVIR N/A
- Revenue This Year
- NUW N/A
- AVIR N/A
- Revenue Next Year
- NUW N/A
- AVIR N/A
- P/E Ratio
- NUW N/A
- AVIR N/A
- Revenue Growth
- NUW N/A
- AVIR N/A
- 52 Week Low
- NUW $12.45
- AVIR $2.46
- 52 Week High
- NUW $14.44
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- NUW 49.35
- AVIR 48.71
- Support Level
- NUW $13.71
- AVIR $3.33
- Resistance Level
- NUW $13.85
- AVIR $3.60
- Average True Range (ATR)
- NUW 0.10
- AVIR 0.16
- MACD
- NUW 0.01
- AVIR -0.02
- Stochastic Oscillator
- NUW 35.88
- AVIR 26.69
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).